A randomized multicenter phase II clinical trial of mitoxantrone-loaded nanoparticles in the treatment of 108 patients with unresected hepatocellular carcinoma
机构：[1]Key Laboratory of Drug Targeting and Drug Delivery Systems, Ministry of Education, West China School of Pharmacy，Sichuan University, Chengdu, China[2]West China Hospital, Sichuan University, Chengdu, China四川大学华西医院[3]Sichuan Provincial Cancer Hospital, Chengdu, China四川省肿瘤医院
Previous studies have demonstrated that intravenous administration of mitoxantrone-loaded polybutylcyanacrylate nanoparticles (DHAD-PBCA-NPs) could allow increased cytotoxicity in hepatic tumors. Therefore, we evaluated the activity and toxicity of DHAD-PBCA-NPs and DHAD injection in individuals with unresected hepatocellular carcinoma. For the DHAD-PBCA-NPs arm the objective response rate was 10.5%, 61.4% patients had stable disease, and 28.1% patients had progression. For the DHAD injection arm no objective response was found, 45.1% patients had stable disease, and 54.9% patients had progression. There were significant differences in both stable disease and progressive disease between the two groups (P<.05). The median survival periods of the DHAD-PBCA-NPs group and the DHAD injection group were 5.46 months and 3.23 months, respectively. Leukopenia was observed in 47.4% and 74.5% of the DHAD-PBCA-NPs arm and the DHAD injection arm, respectively. Meanwhile, anemia was noted in 65% and 37.3% of the DHAD-PBCA-NPs arm and the DHAD injection arm, respectively. From the Clinical Editor: Intravenous administration of mitoxantrone-loaded polybutylcyanacrylate nanoparticles (DHAD-PBCA-NPs) allows increased cytotoxicity in hepatic tumors and prolonged the median survival periods to 5.46 months compared to 3.23 months in controls. (C) 2009 Elsevier Inc. All rights reserved.
基金：
National High Research and Development Program of China [2007AA021800]
基金编号：2007AA021800
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2009]版：
无
最新[2023]版：
大类|2 区医学
小类|3 区医学：研究与实验3 区纳米科技
JCR分区：
出版当年[2009]版：
Q1MEDICINE, RESEARCH & EXPERIMENTALQ1NANOSCIENCE & NANOTECHNOLOGY
最新[2023]版：
Q2MEDICINE, RESEARCH & EXPERIMENTALQ2NANOSCIENCE & NANOTECHNOLOGY
第一作者机构：[1]Key Laboratory of Drug Targeting and Drug Delivery Systems, Ministry of Education, West China School of Pharmacy，Sichuan University, Chengdu, China[2]West China Hospital, Sichuan University, Chengdu, China
共同第一作者：
通讯作者：
通讯机构：[1]Key Laboratory of Drug Targeting and Drug Delivery Systems, Ministry of Education, West China School of Pharmacy，Sichuan University, Chengdu, China[*1]Key Laboratory of Drug Targeting and Drug Delivery Systems, Ministry of Education, West China School of Pharmacy, Sichuan University, Chengdu, China
推荐引用方式(GB/T 7714)：
Zhou Qinghua,Sun Xun,Zeng Lingyuan,et al.A randomized multicenter phase II clinical trial of mitoxantrone-loaded nanoparticles in the treatment of 108 patients with unresected hepatocellular carcinoma[J].NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE.2009,5(4):419-423.doi:10.1016/j.nano.2009.01.009.
APA：
Zhou, Qinghua,Sun, Xun,Zeng, Lingyuan,Liu, Jie&Zhang, Zhirong.(2009).A randomized multicenter phase II clinical trial of mitoxantrone-loaded nanoparticles in the treatment of 108 patients with unresected hepatocellular carcinoma.NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE,5,(4)
MLA：
Zhou, Qinghua,et al."A randomized multicenter phase II clinical trial of mitoxantrone-loaded nanoparticles in the treatment of 108 patients with unresected hepatocellular carcinoma".NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE 5..4(2009):419-423
